Faze Medicines is a biotechnology company focused on developing targeted therapies using advanced gene editing techniques to address genetic disorders. Their approach aims to enhance treatment precision and improve patient outcomes by directly modifying disease-causing genes.
Funding
$81M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Genetic disorders often lack effective treatments due to the difficulty of targeting the underlying disease-causing genes with precision. Traditional therapies may have off-target effects or fail to address the root cause of the condition.
Solution
Faze Medicines is developing targeted therapies using advanced gene editing techniques to directly modify disease-causing genes. This approach aims to enhance treatment precision and improve patient outcomes by addressing the genetic basis of the disorder. By focusing on precise gene modification, Faze Medicines seeks to minimize off-target effects and maximize therapeutic efficacy.
Target Audience
The primary target audience includes patients with genetic disorders and the healthcare providers who treat them.
Features
- Advanced gene editing techniques for targeted therapies
- Direct modification of disease-causing genes
- Enhanced treatment precision
- Improved patient outcomes